Historical salary details - Dr. Robert M. Hershberg, M.D.,PhD, Independent Director, Adaptive Biotechnologies Corp
Dr. Robert M. Hershberg, M.D.,PhD is the Independent Director of Adaptive Biotechnologies Corp. They also hold 3 other positions in Recursion Pharmaceuticals Inc - Ordinary Shares - Class A, Fate Therapeutics Inc and HilleVax Inc.
Dr. Robert M. Hershberg, M.D.,Phd
Independent Director
$ 676.5 K
Gross Remuneration
-
Current Company
Adaptive Biotechnologies Corp
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Adaptive Biotechnologies Corp | Independent Director | 325 K | 0.0 % |
| 2024 | Recursion Pharmaceuticals Inc - Ordinary Shares - Class A | Chairman of the Board | 316.5 K | 4.5 % |
| 2024 | Fate Therapeutics Inc | Independent Director | 35.0 K | - |
| 2024 | HilleVax Inc | Chairman of the Board, President and Chief Executi | - | - |
| 2023 | Adaptive Biotechnologies Corp | Independent Director | 325.0 K | 4.4 % |
| 2023 | Recursion Pharmaceuticals Inc - Ordinary Shares - Class A | Independent Director | 302.7 K | 3.3 % |
| 2023 | Fate Therapeutics Inc | Independent Director | 221.8 K | - |
| 2023 | Fate Therapeutics Inc | Independent Director | - | - |
| 2022 | Adaptive Biotechnologies Corp | Independent Director | 311.3 K | 1.6 % |
| 2022 | Recursion Pharmaceuticals Inc - Ordinary Shares - Class A | Independent Director | 293.1 K | -18.4 % |
| 2022 | ARS Pharmaceuticals Inc | Independent Director | 142.7 K | - |
| 2022 | Nanostring Technologies Inc | Independent Director | 83.2 K | -69.9 % |
| 2022 | Fate Therapeutics Inc | Independent Director | - | - |
| 2022 | HilleVax Inc | Chairman of the Board, President and Chief Executi | - | - |
| 2021 | Fate Therapeutics Inc | Independent Director | 435.2 K | -40.8 % |
| 2021 | Recursion Pharmaceuticals Inc - Ordinary Shares - Class A | Independent Director | 359.3 K | -48.5 % |
| 2021 | Adaptive Biotechnologies Corp | Independent Director | 306.3 K | 40.9 % |
| 2021 | Nanostring Technologies Inc | Independent Director | 276.3 K | 25.1 % |
| 2021 | HilleVax Inc | Chairman of the Board, President and Chief Executi | - | - |
| 2020 | Fate Therapeutics Inc | Independent Director | 735.2 K | - |
| 2020 | Recursion Pharmaceuticals Inc - Ordinary Shares - Class A | Independent Director | 697.7 K | - |
| 2020 | Nanostring Technologies Inc | Independent Director | 220.9 K | 13.3 % |
| 2020 | Adaptive Biotechnologies Corp | Independent Director | 217.5 K | 144.6 % |
| 2019 | Nanostring Technologies Inc | Independent Director | 195.0 K | 128.4 % |
| 2019 | Adaptive Biotechnologies Corp | Independent Director | 88.9 K | 42.0 % |
| 2018 | Nanostring Technologies Inc | Independent Director | 85.4 K | -37.6 % |
| 2018 | Adaptive Biotechnologies Corp | Independent Director | 62.6 K | - |
| 2017 | Nanostring Technologies Inc | Independent Director | 136.7 K | 49.3 % |
| 2016 | Nanostring Technologies Inc | Independent Director | 91.6 K | -15.2 % |
| 2015 | Nanostring Technologies Inc | Independent Director | 108.0 K | - |
| 2014 | Nanostring Technologies Inc | Independent Director | - | - |